ADAR1 promotes cisplatin resistance in intrahepatic cholangiocarcinoma by regulating BRCA2 expression through A‐to‐I editing manner
Cell Proliferation · 2024
DOI: 10.1111/cpr.13659 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Proliferation, 2024. Verfasst von Qi Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Cisplatin, Cholangiocarcinoma, Drug Resistance, Neoplasm, BRCA2 Protein. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation, Guangzhou Science and Technology Project.
Abstract (Originalsprache)
Aberrant A‐to‐I RNA editing, mediated by ADAR1 has been found to be associated with increased tumourigenesis and the development of chemotherapy resistance in various types of cancer. Intrahepatic cholangiocarcinoma (iCCA) is a highly aggressive malignancy with a poor prognosis, and overcoming chemotherapy resistance poses a significant clinical challenge. This study aimed to clarify the roles of ADAR1 in tumour resistance to cisplatin in iCCA. We discovered that ADAR1 expression is elevated in iCCA patients, particularly in those resistant to cisplatin, and associated with poor clinical outcomes. Downregulation of ADAR1 can increase the sensitivity of iCCA cells to cisplatin treatment, whereas its overexpression has the inverse effect. By integrating RNA sequencing and Sanger sequencing, we identified BRCA2 , a critical DNA damage repair gene, as a downstream target of ADAR1 in iCCA. ADAR1 mediates the A‐to‐I editing in BRCA2 3′UTR, inhibiting miR‐3157‐5p binding, consequently increasing BRCA2 mRNA and protein levels. Furthermore, ADAR1 enhances cellular DNA damage repair ability and facilitates cisplatin resistance in iCCA cells. Combining ADAR1 targeting with cisplatin treatment markedly enhances the anticancer efficacy of cisplatin. In conclusion, ADAR1 promotes tumour progression and cisplatin resistance of iCCA. ADAR1 targeting could inform the development of innovative combination therapies for iCCA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
- Key Laboratory of Stem Cells and Tissue Engineering (Sun Yat-sen University), Ministry of Education, Guangzhou, China.
- Department of Animal Experiment Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Laboratory of General Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Department of Laboratory Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Advanced Medical Technology Center, The First Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
ORCID-Profile: Xiao-Yu Yin
Förderung
- National Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
- Guangzhou Science and Technology Project
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Liu, Q., Huang, C. S., Chen, S., Zhu, Y. Q., Huang, X. T., Zhao, G. Y., Xu, Q. C., Shi, Y. H., Li, W., Wang, R., & Yin, X. Y. (2024). ADAR1 promotes cisplatin resistance in intrahepatic cholangiocarcinoma by regulating BRCA2 expression through A‐to‐I editing manner. Cell Proliferation. https://doi.org/10.1111/cpr.13659
Vancouver
Liu Q, Huang CS, Chen S, Zhu YQ, Huang XT, Zhao GY, et al. ADAR1 promotes cisplatin resistance in intrahepatic cholangiocarcinoma by regulating BRCA2 expression through A‐to‐I editing manner. Cell Proliferation. 2024. doi:10.1111/cpr.13659
BibTeX
@article{Liu2024,
author = {Liu, Qi and Huang, Chen-Song and Chen, Siyun and Zhu, Ying-Qin and Huang, Xi-Tai and Zhao, Guang-Yin and Xu, Qiong-Cong and Shi, Yin-Hao and Li, Wen and Wang, Ruizhi and Yin, Xiao-Yu},
title = {ADAR1 promotes cisplatin resistance in intrahepatic cholangiocarcinoma by regulating BRCA2 expression through A‐to‐I editing manner},
journal = {Cell Proliferation},
year = {2024},
doi = {10.1111/cpr.13659}
}
EUVIMED